João Marcello de Araujo Neto

Prof. Dr. João Marcello de Araujo Neto


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
AGAmélio F. Godoy-Matos
Amélio F. Godoy-Matos
CVCynthia Melissa Valério
Cynthia Melissa Valério
WJWellington S. Silva Júnior
Wellington S. Silva Júnior
JNJoão Marcello de Araujo Neto
João Marcello de Araujo Neto
ASAndrei C Sposito
Andrei C Sposito
JSJosé Hermógenes Rocco Suassuna
José Hermógenes Rocco Suassuna
Metabolic Syndrome—a constellation of insulin resistance, cardiovascular risk factors as hyperglycemia, hypertension, and dyslipidemia, and systemic metabolic dysfunction—may be driven by dysregulation of adipose tissue, which manifests as adiposopathy (pathogenic adipose tissue expansion or maldistribution), ectopic fat deposition (in the liver, muscle, pancreas, and cardiorenal systems), and altered secretion of adipokines/hepatokines. Weight gain, obesity, and/or unfavorable fat distribution create a scenario wherein the type, size, location, secretions, or even scarcity of adipocytes drive pathophysiological mechanisms leading to hepatic steatosis and steatohepatitis, type 2 diabetes, and heart and kidney disease. While recent frameworks, such as cardiovascular-kidney-metabolic syndrome, emphasize holistic staging, the central role of metabolic dysfunction-associated steatotic liver disease (MASLD) in multisystem morbidity remains underrecognized. This narrative review synthesizes evidence linking MASLD and diabetes to cardiovascular and kidney diseases through shared pathways of adiposopathy, ectopic lipid accumulation, and dysregulated adipokine/hepatokine signaling. We propose CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome), an expanded pathophysiological model that unifies these interactions into four progressive stages: (1) weight gain and dysfunctional adipose tissue; (2) metabolic risk factors and markers of risk; (3) cardiometabolic diseases and chronic kidney disease; and (4) advanced cardio-renal-liver-metabolic disease. By integrating MASLD as a pivotal component, CARDIAL-MS reframes metabolic syndrome as a continuum of interconnected organ injuries rather than isolated risk factors. CARDIAL-MS provides a staging model to identify patients at critical transition points—from reversible metabolic disturbances to irreversible organ damage. This model emphasizes early interventions targeting adipose tissue health and ectopic fat deposition to mitigate the progression of metabolic cardiorenal diseases. By recognizing the syndromic nature of these conditions, CARDIAL-MS offers clinicians an actionable paradigm for risk stratification, timely diagnosis, and personalized prevention strategies.

19 January 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
AGAmélio F. Godoy-Matos
Amélio F. Godoy-Matos
CVCynthia Melissa Valério
Cynthia Melissa Valério
WJWellington S. Silva Júnior
Wellington S. Silva Júnior
JNJoão Marcello de Araujo Neto
João Marcello de Araujo Neto
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting 30% of the world’s population and is often associated with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease. This review is an update of the Brazilian Diabetes Society (Sociedade Brasileira de Diabetes [SBD]) evidence-based guideline for the management of MASLD in clinical practice. Methods: The methodology was published previously and was defined by the internal institutional steering committee. The SBD Metabolic Syndrome and Prediabetes Department drafted the manuscript, selecting key clinical questions for a narrative review using MEDLINE via PubMed with the MeSH terms [diabetes] and [fatty liver]. The best available evidence was reviewed, including randomized clinical trials (RCTs), meta-analyses, and high-quality observational studies related to MASLD. Results and conclusions: The SBD Metabolic Syndrome and Prediabetes Department formulated 9 recommendations for the management of MASLD in people with prediabetes or T2D. Screening for the risk of advanced fibrosis associated with MASLD is recommended in all adults with prediabetes or T2D. Lifestyle modification (LSM) focusing on a reduction in body weight of at least 5% is recommended as the first choice for these patients. In situations where LSMs are insufficient to achieve weight loss, the use of anti-obesity medications is recommended for those with a body mass index (BMI) ≥ 27 kg/m2. Pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RA) monotherapy are the first-line pharmacological treatments for steatohepatitis in people with T2D, and sodium–glucose cotransporter-2 (SGLT2) inhibitors may be considered in this context. The combination of these agents may be considered in the treatment of steatohepatitis and/or fibrosis, and bariatric surgery should be considered in patients with a BMI ≥ 35 kg/m2, in which the combination of LSM and pharmacotherapy has not been shown to be effective in improving MASLD.

1 February 2020 in Radiology
Verified
Journal Article
Closed access
JNJoão Marcello de Araujo Neto
João Marcello de Araujo Neto

28 February 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
AGAmélio F. Godoy‑Matos
Amélio F. Godoy‑Matos
CVCynthia Melissa Valério
Cynthia Melissa Valério
WJWellington S. Silva Júnior
Wellington S. Silva Júnior
JNJoão Marcello de Araujo Neto
João Marcello de Araujo Neto
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
The colour of the recommendation 8 should be changed from green to orange and the number to be changed from 1 to 11b.

1 November 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
JNJoão Marcello de Araujo Neto
João Marcello de Araujo Neto
HCH. S. M. Coelho
H. S. M. Coelho
MCM. C. Chindamo
M. C. Chindamo
GRG. F. M. Rezende
G. F. M. Rezende
VPV. L. Nunes Pannain
V. L. Nunes Pannain
RPR. M. Perez
R. M. Perez